Name | HIV-1 inhibitor-51 |
---|
Description | HIV-1 inhibitor-51, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exhibits outstanding antiviral activity against WT HIV-1 (IIIB) and a panel of mutant strains. HIV-1 inhibitor-51 has high binding affinity (KD=2.50 μM) and inhibitory activity (IC50=0.03 μM) to WT HIV-1 RT. HIV-1 inhibitor-51 has EC50s of 2.22-53.3 nM for mutant strains(L100I, K103N, Y181C, Y188L, E138K, F227L + V106A, RES056)[1]. |
---|---|
Related Catalog | |
Target |
HIV-1 (WT):0.03 μM (IC50) HIV-1 (WT):2.5 μM (Kd) HIV-1 (L100I):3.04 nM (EC50) HIV-1 (K103N):2.87 nM (EC50) HIV-1 (Y181C):10.2 nM (EC50) HIV-1 (Y188L):13.2 nM (EC50) HIV-1 (E138K):9.77 nM (EC50) HIV-1 (F227L+V106A):19.8 nM (EC50) HIV-1 (RES056):53.3 nM (EC50) |
In Vivo | HIV-1 inhibitor-51 (化合物 36a·HCl; 2 mg/kg; 静脉给药) 的T1/2为1.43小时,CL为103 L/h·kg,Cmax 为 484 ng/mL[1]。 HIV-1 inhibitor-51 (10 mg/kg; 口服) 的 T1/2 为 5.12 小时,Cmax 为 37.5 ng/mL[ 1]。 Animal Model: ICR mice[1] Dosage: 2 mg/kg Administration: IV Result: Had a T1/2 of 5.12 hours, and Cmax of 37.5 ng/mL. |
References |
Molecular Formula | C24H19ClFN5O2 |
---|---|
Molecular Weight | 463.89 |